Patents by Inventor Holger Hess-Stumpp

Holger Hess-Stumpp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
    Patent number: 8796253
    Abstract: This invention relates to novel heteroaryl substituted pyrazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients or therapeutic measures.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: August 5, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Stephen Boyer, Michael Härter, Philip Wickens, Manoj Patel, Ellalahewage Sathyajith Kumarasinghe, Ajay Kumar Bhargava, Karl-Heinz Thierauch, Hartmut Beck, Susanne Greschat, Peter Ellinghaus, Patrick Paulus, Holger Hess-Stumpp
  • NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS
    Publication number: 20110124680
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Application
    Filed: February 2, 2011
    Publication date: May 26, 2011
    Inventors: Rolf BOHLMANN, Martin Haberey, Andreas Huth, Stuart James Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp, Andreas Reichel
  • Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
    Patent number: 7906533
    Abstract: The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Grant
    Filed: November 1, 2005
    Date of Patent: March 15, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp
  • Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
    Patent number: 7902229
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: March 8, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp, Andreas Reichel
  • HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
    Publication number: 20100249085
    Abstract: This invention relates to novel heteroaryl substituted pyrazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients or therapeutic measures.
    Type: Application
    Filed: May 8, 2008
    Publication date: September 30, 2010
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Stephen Boyer, Michael Härter, Philip L. Wickens, Manoj Patel, Ellalahewage Sathyajith Kumarasinghe, Ajay Kumar Bhargava, Karl-Heinz Thierauch, Hartmut Beck, Susanne Greschat, Peter Ellinghaus, Patrick Paulus, Holger Hess-Stumpp
  • METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG
    Publication number: 20100048891
    Abstract: Thiazolidinones of general formula (I) production thereof and use as inhibitors of polo like kinase (PLK) for the treatment of various diseases.
    Type: Application
    Filed: April 29, 2009
    Publication date: February 25, 2010
    Inventors: Klause SCHULZE, Knut Eis, Lars Wortmann, Dirk Kosemund, Olaf Prien, Gerhard Siemeister, Holger Hess-Stumpp, Uwe Eberspaecher, Dominic E.A. Brittain, Imadul Islam
  • VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
    Patent number: 7615565
    Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: November 10, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Andreas Huth, Ludwig Zorn, Martin Kruger, Stuat Ince, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • Effector conjugates, methods for their preparation and their pharmaceutical use
    Patent number: 7605136
    Abstract: Conjugates of epothilones and epothilone derivatives (as effectors) with suitable saccharides or saccharide derivatives (as recognition units) are described. Their production is carried out by the recognition units being reacted with suitable linkers, and the compounds that are produced are conjugated to the effectors. The pharmaceutical use of the conjugates for treating proliferative or angiogenesis-associated processes is described.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: October 20, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Klaus Bosslet, Holger Hess-Stumpp, Jens Hoffmann, Ulrich Klar, Andrea Rotgeri
  • Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
    Patent number: 7572794
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: August 11, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart James Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp
  • VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
    Patent number: 7517894
    Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: April 14, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Andreas Huth, Ludwig Zorn, Martin Krueger, Stuart Ince, Karl Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • Thiazolidinones, their production and use as pharmaceutical agents
    Patent number: 7511059
    Abstract: The invention relates to thiazolidinones of general formula (I) their production and use as inhibitors of polo-like kinases (Plk) for treating various diseases.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: March 31, 2009
    Assignee: Schering Ag
    Inventors: Volker Schulze, Knut Eis, Lars Wortmann, Dirk Kosemund, Olaf Prien, Gerhard Siemeister, Holger Hess-Stumpp, Uwe Eberspaecher, Damian O Arnaiz
  • Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone
    Patent number: 7378522
    Abstract: The invention relates to new quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: May 27, 2008
    Assignee: Zentaris AG
    Inventors: Peter Strehlke, Peter Droescher, Ulrich Buehmann, Norbert Schmees, Peter Muhn, Holger Hess-Stumpp, Roland Kühne, Eckhard Guenther, Emmanuel Polymeropoulos, Antonius M. Ter Laak
  • Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridones
    Publication number: 20070135489
    Abstract: Novel VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are selected.
    Type: Application
    Filed: January 18, 2007
    Publication date: June 14, 2007
    Inventors: Andreas Huth, Martin Krueger, Ludwig Zorn, Stuart Ince, Rolf Bohlmann, Karl Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
    Patent number: 7202260
    Abstract: Novel VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are selected.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: April 10, 2007
    Assignee: Schering AG
    Inventors: Andreas Huth, Martin Krueger, Ludwig Zorn, Stuart Ince, Rolf Bohlmann, Karl Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • Thiazolidinones, their production and use as pharmaceutical agents
    Publication number: 20070037862
    Abstract: Thiazolidinones of general formula I in which Q, A, B, X, R1 and R2 have the meanings that are indicated in the description, as well as those of general formula IA in which Q, A, B, X, R1 and R2a have the meanings that are indicated in the description, their production and use as inhibitors of the polo-like kinase (PLK) for treating various diseases as well as intermediate products for the production of thiazolidinones are described.
    Type: Application
    Filed: November 1, 2004
    Publication date: February 15, 2007
    Inventors: Gerhard Siemeister, Hans Briem, Volker Schulze, Knut Eis, Lars Wortmann, Wolfgang Schwede, Herbert Schneider, Uwe Eberspaecher, Holger Hess-Stumpp
  • Metasubstituted thiazolidinones, their manufacture and use as a drug
    Publication number: 20070015759
    Abstract: This invention involves thiazolidinone of general formula (I) and its creation and use as inhibitors of polo like kinase (PLK) for the treatment of various diseases.
    Type: Application
    Filed: December 14, 2005
    Publication date: January 18, 2007
    Inventors: Volker Schulze, Knut Eis, Lars Wortmann, Dirk Kosemund, Olaf Prien, Gerhard Siemeister, Holger Hess-Stumpp, Uwe Eberspaecher, Dominic Brittain, Imadul Islam
  • VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
    Publication number: 20070015794
    Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.
    Type: Application
    Filed: September 22, 2006
    Publication date: January 18, 2007
    Inventors: Andreas Huth, Ludwig Zorn, Martin Kruger, Stuart Ince, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
    Patent number: 7148357
    Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: December 12, 2006
    Assignee: Schering AG
    Inventors: Andreas Huth, Ludwig Zorn, Martin Kruger, Stuat Ince, Karl-Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • New effector conjugates, methods for their preparation and their pharmaceutical use
    Publication number: 20060276413
    Abstract: Conjugates of epothilones and epothilone derivatives (as effectors) with suitable saccharides or saccharide derivatives (as recognition units) are described. Their production is carried out by the recognition units being reacted with suitable linkers, and the compounds that are produced are conjugated to the effectors. The pharmaceutical use of the conjugates for treating proliferative or angiogenesis-associated processes is described.
    Type: Application
    Filed: August 8, 2006
    Publication date: December 7, 2006
    Inventors: Klaus Bosslet, Holger Hess-Stumpp, Jens Hoffmann, Ulrich Klar, Andrea Rotgeri
  • Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
    Publication number: 20060264425
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Application
    Filed: November 3, 2005
    Publication date: November 23, 2006
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp